Climacteric 2013-02-01

Dydrogesterone does not reverse the cardiovascular benefits of percutaneous estradiol.

V M Kuba, M A M Teixeira, R M R Meirelles, C R L Assumpção, O S Costa

Index: Climacteric 16(1) , 54-61, (2013)

Full Text: HTML

Abstract

To evaluate the influence of dydrogesterone on estimated cardiovascular risk of users of hormone replacement therapy (HRT) (with percutaneous 17β-estradiol in monotherapy and in combination with dydrogesterone) and HRT non-users through the Framingham score tool for a period of 2 years.Framingham scores were calculated from the medical records of patients treated for at least 2 years with 17β-estradiol alone or in combination with dydrogesterone, along with HRT non-users, through the analysis of patient medical records, followed for at least 2 years at Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione.Improvements in lipid profile, glucose and blood pressure levels, which reduced the estimated cardiovascular risk, were observed in the 17β-estradiol group. Similar changes were observed in the users of 17β-estradiol + dydrogesterone, suggesting that this progestogen does not attenuate the effects caused by 17β-estradiol.Both HRT groups showed a reduction in their Framingham score. In contrast to data from other HRT investigations on cardiovascular risk, these formulations proved to be safe, even in the first year of use.

Related Compounds

  • 6-Dehydroprogester...
  • Dydrogesterone

Related Articles:

Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.

2013-02-01

[Gynecol. Endocrinol. 29(2) , 165-8, (2013)]

Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety.

2013-09-01

[Maturitas 76(1) , 10-21, (2013)]

Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.

2012-01-01

[Neuro Endocrinol. Lett. 33(7) , 697-702, (2012)]

Beneficial influence of postmenopausal estrogen therapy on serum adhesion molecules is independent of the route and dose of administration.

2011-01-01

[Neuro Endocrinol. Lett. 32(3) , 340-4, (2011)]

Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report.

2013-11-01

[Jpn. J. Clin. Oncol. 43(11) , 1145-9, (2013)]

More Articles...